Cell-directed focal proteolysis by plasma membrane-associated proteinases is critical to a number of physiological and pathological processes, including tissue remodeling, angiogenesis, and leukocyte and tumor cell migration (1) . Although many proteinases are involved, members of the matrix metalloproteinase (MMP 1 ) family and in particular MMP-2 (gelatinase A, EC 3.4.24.24), play a pivotal role in these events. MMPs are a group of zinc-dependent endopeptidases that in vitro have the potential to degrade proteins of the extracellular matrix (1), although in vivo evidence for this is limited. MMPs also process a number of bioactive molecules (2, 3) . MMP activity is under tight regulation at several levels, including activation of the MMP zymogens and specific inhibition by the tissue inhibitors of metalloproteinases (TIMPs). The largest sub-family of the MMPs is the membrane-type (MT)-MMPs, which are localized to the cell surface via either a transmembrane domain (4 -7) or a glycosylphosphatidylinositol anchor (8, 9) . In addition, a number of secreted MMPs are recruited to and activated at the cell surface such as MMP-2 and MMP-13 (10, 11) .
MT-MMPs play a dual role in cell surface proteolysis: Not only do they cleave a variety of extracellular components (12, 13) , but they activate some secreted MMPs. The TIMP-2-dependent activation of MMP-2 by MT1-MMP via the formation of a trimolecular complex has been described in detail (4, 14, 15) . Active MT1-MMP binds the amino-terminal domain of TIMP-2 (16 -18) whereas the carboxyl-terminal domain (C domain) of the TIMP-2 molecule interacts with the hemopexin C domain of pro-MMP-2 (14, 19 -21) . Activation of the tethered pro-MMP-2 is executed by a second active MT1-MMP to form a 68-kDa intermediate (22, 23) . Fully activated MMP-2 is then generated by an autocatalytic cleavage in trans (22, 24) . The absolute dependence of this pathway on the presence of TIMP-2 was shown in vivo using Timp2Ϫ/Ϫ mice (25, 26) and in vitro using a Timp2Ϫ/Ϫ cell line transfected to express MT1-MMP on the cell surface (27, 28) . Despite binding to the hemopexin C domain of MMP-2 and inhibiting MT1-MMP (28, 29) , TIMP-4 was unable to substitute for TIMP-2 in MMP-2 activation (28) . MT1-MMP appears to be the major activator of MMP-2 as shown using MT1-MMP null mice, however, some activation of MMP-2 in these mice was observed (30) . Indeed other members of the MT-MMP sub-family have been shown to activate MMP-2, using either catalytic domains in vitro (MT-MMPs 2, 4, and 5) (13, (31) (32) (33) or the full-length molecule expressed in mammalian cells (MT-MMPs 3, 5, and 6) (6, 34, 35) . However, the requirement for TIMP-2 in MMP-2 activation by MT-MMPs 2-6 has not been demonstrated, nor has the potential role of TIMP-4 in MMP-2 activation by these MT-MMPs been addressed.
MT2-MMP was originally isolated from a human lung cDNA library (5) , and expression in a wide variety of normal (5, 36) and malignant (37) (38) (39) tissues has been reported. Expression of MT2-MMP in glioblastomas correlated with MMP-2 activation and degree of malignancy (40) , and expression of MT2-MMP in COS cells was found to confer invasiveness (41) . Although the soluble MT2-MMP catalytic domain produced in Escherichia coli was shown to activate MMP-2 in the absence of TIMP-2 in vitro (31, 32) , this was thought to occur due to an unphysiologically high concentration of the MT2-MMP. Other reports are unclear regarding the potential for the cellular activation of MMP-2 by full-length MT2-MMP, and the requirement for TIMP-2 has not specifically been addressed. Human and mouse MT2-MMP expressed in COS cells were reported to activate MMP-2 (42) , although a second study by the same group suggested that human MT2-MMP was defective in MMP-2 processing (43) . Very recently MT2-MMP and MT1-MMP were shown to activate MMP-2 in a pathway mediated by the tight junction protein of endothelial cells, claudin 5 (44) .
In this study, the role of TIMP-2 and TIMP-4 in the cellular activation of MMP-2 by MT2-MMP was investigated by expressing hMT2-MMP in a Timp2Ϫ/Ϫ cell line. We report that MT2-MMP efficiently activates MMP-2 in a TIMP-2-independent pathway at the cell surface, with TIMP-2 and TIMP-4 regulating activation by inhibiting MT2-MMP.
EXPERIMENTAL PROCEDURES
Recombinant MT2-MMP Expression Vector-A cDNA encoding fulllength hMT2-MMP (kindly supplied by Dr. H. Will, Invetek, Berlin, Germany) was cloned into the mammalian expression vector pGW1GH (generously provided by Dr. J. M. Clements, British Biotech Pharmaceuticals, Oxford, UK) (designated pGW1GH/hMT2-MMP) and fully sequenced.
Cell Culture and Transfection-Ras/Myc-transformed Timp2Ϫ/Ϫ skin fibroblasts (25) were cultured in Dulbecco's modified essential medium (DMEM) (Life Technologies, Inc.) supplemented with 10% Cosmic calf serum (HyClone Laboratories, Inc.) at 37°C in a humidified atmosphere containing 5% CO 2 . Timp2Ϫ/Ϫ cells were transfected with linearized pGW1GH/hMT2-MMP or pGW1GH plasmids in phosphatebuffered saline (PBS) (138 mM NaCl, 2.7 mM KCl, 20 mM Na 2 HPO 4 , 1.5 mM KH 2 PO 4 , pH 7.4) using a Bio-Rad Gene Pulser II at 25 microfarads of capacitance and 1.2 kV as described for hMT1-MMP (28) . Transfected cells were cultured in selection medium: DMEM with 10% Cosmic calf serum, 25 g/ml mycophenolic acid, 250 g/ml xanthine, and 100 M hypoxanthine/16 M thymidine supplement (Life Technologies, Inc.). After 10 -12 days, 65 clones were screened for expression of MT2-MMP. Sixteen positive clones were selected based on their ability to fully activate pro-MMP-2 in conditioned medium from rat osteosarcoma (ROS) 17/2.8 cells, which also contains TIMP-2 (45). Clones were expanded and maintained in selection medium, and two clones #4.7 and #42 were primarily used in experiments. Timp2Ϫ/Ϫ cells transfected for stable expression of hMT1-MMP, as described in Bigg et al. (28) , were also used.
Non-quantitative RT-PCR-Total RNA was prepared using RNeasy (Qiagen) from 5 ϫ 10 6 untransfected and transfected Timp2Ϫ/Ϫ cells in exponential growth phase cultured in the presence and absence of 20 g/ml concanavalin A (ConA) (Sigma Chemical Co.) (46) . The RNA was treated with DNase I and reverse transcribed using an oligo(dT) primer and Superscript II (Life Technologies, Inc.) was performed as described in Morrison et al. (60) . Control reactions contained no reverse transcriptase (RT). PCR reactions were performed (30 cycles of amplification: 1 min at 94°C, 1 min at 55°C, 2 min at 72°C) on 2 l of RT reaction using specific primer pairs: MMP-2 (sense 5Ј-GGTTTATTTG-GCGGAC-3Ј; antisense 5Ј-TCAGCAGCCCAGCCAGTC-3Ј); MT1-MMP (sense 5Ј-GGGCCCAACATCTGTGAC-3Ј; antisense 5Ј-GCAGCCCATC-CAGTCC-3Ј); MT2-MMP (sense 5Ј-CCGGTGTGCTCGACGAAGAC-3Ј; antisense 5Ј-CCGCTCTGGCTTCCCACCTGG-3Ј); TIMP-1 (sense 5Ј-T-CTGGCATCTGGCATCCTC-3Ј; antisense 5Ј-AGCAAAGTGACGGCTG-CTCTGG-3Ј); TIMP-2 (sense 5Ј-GCGGTCAGTGAGAAGGAAGTGG-3Ј; antisense 5Ј-CTTGCACTCGCAGCCCATCTG-3Ј); TIMP-3 (sense 5Ј-G-CCTTCTGCAACTCCGAC-3Ј; antisense 5Ј-GCCCATCCTCGGTACCA-G-3Ј); TIMP-4 (sense 5Ј-CCCTGCTGACACTCAAAA-3Ј; antisense 5Ј-C-TAGGGCTGAACGATGTC-3Ј); and Neomycin (Neo) (sense 5Ј-TGGAG-AGGCTATTCGGCTAT-3Ј; antisense 5Ј-CGCCAAGCTCTTCAGCAAT-A-3Ј). Plasmids (10 ng) containing the relevant murine cDNAs were used as positive controls.
Quantitative Real Time RT-PCR-RNA was isolated from 5 ϫ 10 6 untransfected and transfected Timp2Ϫ/Ϫ cells cultured in the absence of ConA and reverse-transcribed as described. Real time PCR was performed (10 s at 94°C, 60 s at 60°C for 40 cycles of amplification) on an Applied Biosystems Amp 5700 Sequence Detection System using specific primers pairs for: hMT2-MMP (sense 5Ј-TGGTGGCAGTGCA-TGAGC-3Ј; antisense 5Ј-GGCAGCTTGAAGTTGTCAACG-3Ј) and (sense 5Ј-GTCCTGGACAACTATCCCATGC-3Ј; antisense 5-CGCTTCT-CGAAAGAGCCAGTAG-3Ј); hMT1-MMP (sense 5Ј-GCCTACCGACAA-GATTGATGC-3Ј; antisense 5Ј-CACTGCCCTGAGCTCTTCG-3Ј) and (sense 5Ј-GAGGAAGGATGGCAAATTCG-3Ј; antisense 5-GCATCAAT-CTTGTCGGTAGGC-3Ј); murine and hMT1-MMP (sense 5Ј-ACGGGA-ACTTTGACACCGTG-3Ј; antisense 5-TTATTCCTCACCCGCGAG-3Ј); and glyceraldehyde-3-phosphate dehydrogenase (sense 5Ј-GTATGACT-CCACTCACGGCAAA-3Ј; antisense 5Ј-CCATTCTCGGCCTTGACTGT-3Ј). 30-l reactions contained: 1 l of RT reaction, 400 nM of each set of specific sense and antisense primers as appropriate, 15 l of Sybergreen PCR mix (Applied Biosystems), and 5% Me 2 SO. Standard curves were generated using 10 3 -10 8 copies of plasmids containing cDNA of hMT1-MMP or hMT2-MMP, and results were normalized for RNA input using glyceraldehyde-3-phosphate dehydrogenase. Samples and standards were analyzed in triplicate for each set of primers for MT1-MMP and MT2-MMP cDNAs, and control reactions without RT were analyzed in duplicate.
Immunocytochemistry-For immunocytochemical studies, untransfected and transfected Timp2Ϫ/Ϫ cells were seeded at 2 ϫ 10 4 cells/well onto eight-well chamber slides (Lab-Tek). Cells were cultured for 24 h, washed in PBS, and incubated in serum-free DMEM with or without 20 g/ml ConA. After 24-h incubation, the medium was removed and cells were fixed in 4% paraformaldehyde in PBS for 20 min and washed four times in PBS. The fixed cultures were incubated overnight at 4°C in Tris-buffered saline (TBS) (150 mM NaCl, 20 mM Tris, pH 7.5) containing 2% bovine serum albumin (BSA) (TBS-BSA) and 10% normal goat serum (Molecular Probes). Designated wells were incubated with 2.5 g/ml mouse monoclonal antibody against hMT1-MMP (MAB918) (R & D Systems, Inc.), 2.5 g/ml rabbit polyclonal antibody against MT1-MMP (AB815) (Chemicon), 20 g/ml mouse monoclonal antibody against MT2-MMP (MAB3220) (Chemicon), 2.5 g/ml affinity-purified rabbit polyclonal antibodies that we raised against the following peptide sequences in hMT2-MMP, , using methods described before (21) , control mouse immunoglobulin (Dako), control non-immune rabbit serum (Molecular Probes), or TBS-BSA alone, for 2 h at 20°C and then washed four times with excess TBS. Texas Red-conjugated goat anti-mouse IgG or anti-rabbit IgG antiserum (Molecular Probes) diluted in TBS-BSA to 1%, was added to appropriate samples. Secondary antibodies were highly pre-absorbed against other species' IgG by the supplier and further screened in our laboratory, in pilot experiments, to verify lack of nonspecific binding to cultured cells as described (21) . The cells were washed four times in TBS and incubated in 10 M Hoechst 33342 in TBS for 10 min, then washed again four times in TBS. The chambers were disassembled, and coverslips were applied to the slides over 10% (w/v) 1,4-diazobicyclo-2,2-octane (Sigma) in 90% glycerol/10% PBS. Preparations were viewed using a Zeiss Axioskop fluorescence microscope with Plan-Neofluar objectives and standard filters for Texas Red and Hoechst, respectively. High resolution monochrome images were collected on a charge-coupled device camera and processed using a Northern Eclipse software package. Exposure times for antibody-stained, non-immune control and no primary antibody control incubations were standardized at identical exposure times to obtain representative control images. Images were colorized with Photoshop 5.0 using identical settings.
Recombinant Proteins-Human TIMP-2 and TIMP-4 were expressed in Chinese hamster ovary (CHO) and baby hamster kidney cells, respectively, and purified as described in Bigg et al. (28) . TIMP-2-free human pro-MMP-2 was expressed in Timp2Ϫ/Ϫ cells using the pGW1GH expression vector as described (28) . A hemopexin C domain deletion mutant of human pro-MMP-2 (MMP-2⌬CD) was prepared. 2 To introduce a stop codon, two bases were mutated in pGW1GH/hMMP-2 at base positions 1252 and 1253 (TCT to TGA) in the MMP-2 cDNA. MMP-2⌬CD cDNA was then fully sequenced, and pGW1GH/hMMP-2⌬C was transfected into CHO cells as described for the Timp2Ϫ/Ϫ cells. Clones expressing MMP-2⌬CD (M r ϭ 46,000) were identified by zymography and expanded under selection. MMP-2 hemopexin C domain was expressed in E. coli and purified as described (21, 47) . Recombinant hMT2-MMP catalytic domain was generously provided by Dr. H. Will (32) . Cell Assays-Untransfected Ras/Myc-transformed Timp2Ϫ/Ϫ cells and cells transfected with vector, hMT2-MMP, or hMT1-MMP were seeded into 96-microwell or 6-well tissue culture plates at 2.5 ϫ 10 4 or 5 ϫ 10 5 cells per well, respectively. After 24 h the cells were washed twice with PBS and then incubated serum-free in DMEM containing recombinant TIMP-2-free pro-MMP-2 (final concentration 5 nM) or MMP-2⌬CD (final concentration 5 nM) or with conditioned serum-free medium from ROS 17/2.8 cells containing pro-MMP-2 and TIMP-2. Cell supernatants were harvested after 24 h and for some experiments cell monolayers were detached by pipetting up and down in PBS, washed thoroughly with PBS (3 ϫ 1.5 ml), and lysed in 0.2% Zwittergent (Calbiochem). Cell extracts and supernatants were analyzed by zymography. For activation of MMP-2 in the presence of TIMP-2 and TIMP-4, between 0 and 81 nM TIMP-2 or TIMP-4 was added in serum-free DMEM containing 5 nM recombinant TIMP-2-free pro-MMP-2. In other experiments, cells were treated with 20 g/ml ConA in serum-free DMEM containing 5 nM recombinant TIMP-2-free pro-MMP-2 and incubated for 24 h. In MMP-2 hemopexin C domain competition experiments, cells were incubated with 50 l of serum-free DMEM containing 1-5000 nM hemopexin C domain (0.1-to 500-fold molar ratio of hemopexin C domain to pro-MMP-2 final concentration) for 2 h, followed by the addition of 50 l of DMEM containing 10 nM recombinant TIMP-2-free pro-MMP-2. For ConA and hemopexin C domain competition experiments, cells expressing hMT1-MMP and the vector control cells were also incubated in the presence of 3 nM TIMP-2
Gelatin Zymography-Samples were electrophoresed under non-reducing conditions on 10% polyacrylamide gels co-polymerized with 1 mg/ml gelatin. Zymograms were incubated in TBS with 5 mM CaCl 2 at 37°C for 4 -24 h before staining with Coomassie Brilliant Blue R250.
Kinetic Analysis of MT2-MMP and TIMP-4 -To measure the association rate constant (k on ) of MT2-MMP and TIMP-4, the concentration of the hMT2-MMP catalytic domain was assessed by active site titration against TIMP-2 of known concentration. MT2-MMP activity was measured in fluorometry assay buffer (0.1 M Tris-HCl, pH 7.5, 0.1 M NaCl, 10 mM CaCl 2 , 0.05% Brij 35) at 25°C using 1 M of the general MMPquenched fluorescent peptide substrate (7- (48) . 10 nM MT2-MMP was inhibited by similar concentrations of TIMP-2 and TIMP-4, and the k on was calculated from curves fitted to the data using a slow tight binding equation (Method 2 (49)). To estimate the overall inhibition constant, MT2-MMP (350 pM to 2.8 nM) was incubated in fluorometry assay buffer with a range of concentrations of TIMP-1, TIMP-2, or TIMP-4 (up to 765 nM) for at least 2 h at 37°C in a 96-well fluorescence assay plate. Remaining activity was measured at 37°C using 1 M quenched fluorescent peptide in a Fmax fluorescence plate reader (Molecular Devices) with a 320-nm excitation and 405-nm emission filter pair. Data were fitted to a tight binding equation (see Ref. 19 ) to obtain an estimate for K i (app) as described previously (28) .
RESULTS

Characterization of the Ras/Myc-transformed Timp2Ϫ/Ϫ
Cell Line-To study the cellular activation of MMP-2 by MT2-MMP and to address the role of TIMP-2 and TIMP-4 in this activation pathway, we utilized a Ras/Myc-transformed skin fibroblast cell line derived from a Timp2Ϫ/Ϫ mouse (25) . The Timp2Ϫ/Ϫ cells expressed mRNA of MMP-2, MT1-MMP, and TIMP-1 and TIMP-3 but did not express MT2-MMP, TIMP-2, or TIMP-4 mRNAs (Fig. 1A) as assessed by non-quantitative RT-PCR. The presence of ConA did not appear to alter the expression profile of the mRNAs in this assay. Expression of the mRNA encoding Neo resistance was used as a positive control, because Neo was the selectable marker in the original targeted replacement of the Timp2 gene in embryonic stem cells (25) .
We examined the ability of the Timp2Ϫ/Ϫ cells to activate either endogenously produced MMP-2 or exogenous recombinant TIMP-2-free hMMP-2 expressed in transfected Timp2Ϫ/Ϫ cells. In the absence of TIMP-2, the Timp2Ϫ/Ϫ cell line was unable to activate either endogenous or exogenous pro-MMP-2 even after stimulation with ConA (Fig. 1B) . However, in the presence of TIMP-2, activation of pro-MMP-2 to the fully active form was observed after 24-h stimulation with ConA (Fig. 1C) . Without ConA treatment no activation of MMP-2 occurred (Fig.  1C) even though MT1-MMP mRNA was present (Fig. 1A) , suggesting that ConA was required for elevated MT1-MMP expression and/or trafficking and clustering of the MT1-MMP at the cell surface. Immunocytochemical analysis of the Timp2Ϫ/Ϫ cells using MT1-MMP-specific antibodies revealed that MT1-MMP protein expression was induced only after treatment with ConA for 24 h (Fig. 1D , Panel ii compared with Panel i). The lacunar pattern of cell surface staining closely resembled that seen before for MT1-MMP in ROS 17/2.8 cells (21) . Consistent with the mRNA expression data, MT2-MMP protein expression was not detected in the Timp2Ϫ/Ϫ cells by immunocytochemistry (data not shown). The inability of the cells to activate MMP-2 in the absence of ConA and their lack of TIMP-2 and TIMP-4 expression make this an ideal system in which to study the role of these TIMPs in the cellular activation of MMP-2 by MT2-MMP. In addition, because the role of TIMP-2 and TIMP-4 in MT1-MMP-mediated activation of pro-MMP-2 has been well characterized, Timp2Ϫ/Ϫ cells expressing hMT1-MMP (28) were included in experiments as controls.
Cellular Activation of MMP-2 by MT2-MMP Is TIMP-2-independent-Stable
Timp2Ϫ/Ϫ cell lines constitutively expressing MT2-MMP on the cell surface were generated by transfection with the mammalian expression vector pGW1GH/hMT2-MMP. The hMT2-MMP cDNA contained a single base pair substitution from the published sequence (5) at position 1787 (A to G), which results in an amino acid change at position 596 (Asp to Gly) carboxyl-terminal to the hemopexin C domain within the glycine-rich linker that connects to the transmembrane domain. Independently we found this base pair substitution in three separate cDNA clones amplified from a second source, a human gingival fibroblast cDNA library (2) , and therefore this may represent a natural polymorphism.
Sixteen independent clones were selected during screening in serum-free medium containing pro-MMP-2 and TIMP-2 that, unlike untransfected cells (Fig. 1C) , activated pro-MMP-2 without the addition of ConA (data not shown). These MT2-MMP-expressing clones were then characterized under TIMP-2 free conditions, by the addition of 5 nM TIMP-2-free pro-MMP-2. Surprisingly, we found that all 16 clones could also activate pro-MMP-2 in the absence of TIMP-2. Activation of MMP-2 occurred via the 68-kDa intermediate, as shown for five clones in Fig. 2 . Similarly, activation of the low levels of endogenous pro-MMP-2 by the MT2-MMP-expressing cells was also observed in the absence of TIMP-2 (detected after incubation of zymograms for 24 h compared to 3 h for exogenous pro-MMP-2, data not shown). In contrast to the cells expressing MT2-MMP, Timp2Ϫ/Ϫ cells transfected with the vector only were unable to activate MMP-2 in the presence (Fig. 4C) or absence (Fig. 2 , Vector) of TIMP-2. Because serum contains low levels of TIMPs (50) , these experiments were conducted under serum-free conditions following thorough washing of the cells in PBS. To confirm that cultures were truly TIMP-2-free, culture supernatants were concentrated 10-fold and analyzed by reverse zymography, but no TIMP-2 was detected even after prolonged incubation of the reverse zymograms (data not shown). These data showed that cell surface-expressed MT2-MMP activated MMP-2 to its fully active form in a TIMP-2-independent manner.
Rate of Activation of MMP-2 by MT2-MMP via the TIMP-2-independent Pathway-To assess the efficiency of MMP-2 activation by MT2-MMP, we compared the rate of activation to that mediated by hMT1-MMP. Time course experiments were performed using Timp2Ϫ/Ϫ cells expressing hMT2-MMP or MT1-MMP incubated in the absence and presence of ConA. As shown in Fig. 3A , activation of exogenous MMP-2 by MT2-MMP in the absence of TIMP-2 occurred rapidly, and activated MMP-2 was detected in cell culture supernatants within 4 h. The 4-h lag period before activation occurred was essentially unaltered by ConA, however, an increased amount of activated MMP-2 was observed at 24 and 48 h in the presence of ConA (Fig. 3A) . Because no TIMP-2 was present, this increase in MMP-2 activation could not be the result of endogenous MT1-MMP induced by ConA, which is absolutely dependent on TIMP-2 to generate the 62-kDa fully active form (see Fig. 1B ). . D, immunocytochemistry of cells using a MT1-MMP-specific antibody. Cells were cultured with and without ConA for 24 h and stained using a mouse monoclonal MT1-MMP-specific antibody (panels i and ii) or control antibody (panels iii and iv) followed by a goat anti-mouse antibody conjugated to fluorescein isothiocyanate. Arrowheads, MT1-MMP-specific staining of cell membranes. Similar results were observed using the rabbit polyclonal MT1-MMP-specific antibody. The position of the cells is shown using a Hoechst nuclear stain (panels i-iv).
In contrast, MMP-2 activation by cells expressing MT1-MMP in the presence of TIMP-2 occurred more slowly and was first observed at 12 h, but activation was accelerated by ConA with a reduction in the lag period to 4 h (Fig. 3B) . Because ConAinduced activation of MMP-2 by endogenous MT1-MMP occurred around 24 h as shown in the presence of TIMP-2 for the vector control (Fig. 3B) and untransfected Timp2Ϫ/Ϫ cells (Fig.  1C) , the reduction in the lag period may be due to increased efficiency of activation following clustering on the cell surface of the constitutively expressed recombinant MT1-MMP. Induction of endogenous MT1-MMP likely accounts for the enhanced level of activation observed at 24 and 48 h in the presence of ConA and 3 nM TIMP-2. Hence, in the absence of ConA, activation of MMP-2 by MT2-MMP via the TIMP-2-independent pathway occurred more rapidly than the TIMP-2-dependent activation of MMP-2 by MT1-MMP.
Levels of Recombinant MT2-MMP Expression-We compared the expression levels of clones expressing MT2-MMP versus MT1-MMP, to determine if marked differences in MT-MMP levels accounted for the differences observed in MMP-2 activation. To quantitatively compare expression levels in individual clones expressing different proteins, we determined the relative mRNA levels of MT1-MMP and MT2-MMP using quantitative real time RT-PCR (51, 52) . In transfected cells expressing recombinant MT1-MMP, the expression level of MT1-MMP was increased Ͼ10-fold over the endogenous level (Table I) . Clones transfected with MT2-MMP had similar levels of mRNA expression, which was 5-to 10-fold lower than the recombinant hMT1-MMP expression levels in the MT1-MMP transfectants (Table I ). Highly consistent levels of endogenous mMT1-MMP expression (between 0.2 and 0.3 ϫ 10 6 mRNA copies/10 4 cells) were found for the clones expressing hMT1-MMP and hMT2-MMP, and the control cells transfected with the vector alone ( Table I ), indicating that the transfections did not alter endogenous MT1-MMP expression. The mRNA copy numbers for both hMT1-MMP and hMT2-MMP were confirmed using a second set of primers.
Quantitative real time RT-PCR demonstrated MT2-MMP mRNA expression in MT2-MMP transfectants and activation of exogenous MMP-2 by the transfectants indicated that MT2-MMP was localized to the cell surface. However, in contrast to the expression levels of MT1-MMP protein, which was readily detectable in the MT1-MMP transfectants by Western blot analysis, the recombinant MT2-MMP protein expression levels were found to be low, close to the threshold of detectability for four different antibodies to MT2-MMP using Western blot, immunocytochemistry, and flow cytometry analyses (data not shown). The 10-fold-lower expression level of hMT2-MMP compared with hMT1-MMP in transfectants suggests that activation of MMP-2 in a TIMP-2-independent manner was not simply occurring as the result of a high local concentration of MT2-MMP. 
TIMP-2 and -4 Inhibit MMP-2 Activation by MT2-MMP-We
TABLE I Expression levels of MT1-MMP and MT2-MMP in transfected
Timp2Ϫ/Ϫ cells Quantitative real-time RT-PCR was used to determine the MT1-MMP and MT2-MMP mRNA copy number in Timp2Ϫ/Ϫ cells expressing hMT2-MMP or hMT1-MMP or transfected with the vector alone. Primers specific for hMT2-MMP, hMT1-MMP, or both murine and hMT1-MMP were used. Standard plasmid curves were used to determine mRNA copy number, and input RNA was normalized using glyceraldehyde-3-phosphate dehydrogenase. Samples were analyzed in triplicate and were all within 5%. MT2-MMP expressing clone (#42) (data not shown). In contrast, Timp2Ϫ/Ϫ cells expressing recombinant MT1-MMP were unable to fully activate MMP-2 in the absence of TIMP-2 (Fig.  4B, lane 0) . Within a narrow range of TIMP-2 concentration (0.3-9 nM) the efficiency of MMP-2 activation by MT1-MMP was greatly improved, and the fully active form of MMP-2 was generated. TIMP-4 was unable to support activation of MMP-2 by MT1-MMP (Fig. 4B) as previously reported (28) . Control cells transfected with the vector only did not activate MMP-2 in the presence or absence of either TIMP-2 or TIMP-4 (Fig. 4C) . Hence, activation of MMP-2 by MT2-MMP was not enhanced by either TIMP-2 or -4 but was inhibited by both at higher concentrations.
TIMP-4 Inhibits MT2-MMP-To elucidate the mechanism by which TIMP-4 blocked MMP-2 activation by MT2-MMP, we determined whether TIMP-4 inhibited MT2-MMP. The association rate constants (k on ) for the binding of TIMP-4 and TIMP-2 to the catalytic domain of MT2-MMP are shown in Table II (28) . The K i(app) for TIMP-4 and TIMP-2 inhibition of MT2-MMP were below the lowest enzyme concentration that could be used (350 pM), due to the low specific activity of MT2-MMP for the fluorescent substrate. We were able to measure the K i(app) of MT2-MMP for TIMP-1, because this is a relatively poor inhibitor of MT2-MMP (Table II) . Comparison with our previous data (28) indicates that TIMP-1 is a slightly better inhibitor of MT2-MMP (K i(app) 100 nM) than MT1-MMP (K i(app) 147 nM), which was also suggested by the relative k on values (31), but the K i(app) values had not previously been determined. The fact that we could not accurately measure the K i(app) for TIMP-4 inhibition of MT2-MMP below ϳ350 pM suggests that, like TIMP-2, TIMP-4 is a relatively efficient inhibitor of MT2-MMP. Hence, it is likely that the TIMP-4-mediated inhibition of MMP-2 activation in the cells expressing MT2-MMP is a result of MT2-MMP inhibition.
Activation of MMP-2 by MT2-MMP Involves Cell Association of MMP-2-
To determine whether cell surface interaction of MMP-2 is required for activation by MT2-MMP, we analyzed the cell extracts of clones expressing MT2-MMP following incubation with exogenous pro-MMP-2 (Fig. 5) . Because endogenous levels of MMP-2 were very low (Fig. 5, lanes 1, 4, 7, and  10) , the MMP-2 detected in the cell extracts (Fig. 5, lanes 5, 6,  8, 9 , and 12) largely represents exogenous MMP-2 associated with the cell surface. Activation intermediate and fully active MMP-2 were detected in cell extracts from two independent clones expressing MT2-MMP (#4.7 and #42) whether or not TIMP-2 was present (Fig. 5, lanes 5, 6, 8, and 9) . Similarly, activation of exogenous pro-MMP-2 to intermediate and fully active forms was observed in supernatants from these MT2-MMP clones in the absence or presence of 3 nM TIMP-2 (Fig. 5,  lanes 5, 6, 8, and 9 ). MMP-2 was detected in MT1-MMP-transfectant cell extracts only in the presence of 3 nM TIMP-2 (Fig.  5, lane 11 compared with 12) , confirming the tethering role of TIMP-2 in the MT1-MMP trimolecular complex. Moreover, full activation of MMP-2 by MT1-MMP was observed in supernatants only in those cultures incubated with TIMP-2 (Fig. 5, lane  12) . In the absence of TIMP-2, MMP-2 was processed to the intermediate form only (Fig. 5, lane 11 ; see also Fig. 4B ). As previously reported (21, 28) , it is only the second intermolecular autocatalytic cleavage step that is absolutely TIMP-2-dependent. Very low levels of pro-MMP-2 were detected in vector control cell extracts, and only pro-MMP-2 was observed in the supernatant (Fig. 5, lanes 2 and 3) . These data showed that activation by MT2-MMP in a TIMP-2-independent manner involves cell surface association of the MMP-2.
Activation of MMP-2 by MT2-MMP Is MMP-2 Hemopexin C Domain-dependent-To determine the nature of the cell surface interaction of MMP-2 involved in processing by MT2-MMP, we performed competition experiments using recombinant MMP-2 hemopexin C domain. Clone #42 expressing MT2-MMP was incubated with 0-to 500-fold molar ratio of recombinant hemopexin C domain to exogenous MMP-2. Activation of pro-MMP-2 to the fully active form by MT2-MMP in the absence of TIMP-2 was blocked by Ͼ10-fold molar excess of hemopexin C domain with accumulation of the intermediate form of MMP-2 observed at higher concentrations (Fig. 6A) . Similarly, activation of MMP-2 by MT1-MMP in the presence of 3 nM TIMP-2 was also blocked by the addition of a ϳ10-fold molar excess of hemopexin C domain (Fig. 6B) . No activation of MMP-2 by the vector control cells occurred in the presence or absence of hemopexin C domain (Fig. 6C) . These results suggest that the second activation step of MMP-2 by the MT2-MMP pathway is MMP-2 hemopexin C domain-dependent.
To verify the dependence of MT2-MMP processing of MMP-2 on hemopexin C domain interactions, we determined whether MT2-MMP could activate recombinant MMP-2⌬CD, which lacks the hemopexin C domain (Fig. 7) . Clones expressing MT2-MMP (#4.7 and #42) were incubated with either fulllength or MMP-2⌬CD in the absence of TIMP-2. MMP-2⌬CD was not activated by the MT2-MMP-expressing clones, and pro-MMP-2⌬CD was detected only in culture supernatants and was not associated with cell extracts (Fig. 7, lanes 5 and 7) . In contrast, processing by MT2-MMP of full-length MMP-2 to the 62-kDa form via the intermediate was observed in cell supernatants and extracts (Fig. 7, lanes 4 and 6) . Moreover, autolytic processing of the activated full-length MMP-2 to generate MMP-2⌬CD was seen in cell supernatants, but MMP-2⌬CD was never detected in cell extracts (Fig. 7, lanes 4 and 6) . Activation of MMP-2 by MT1-MMP is known to be hemopexin C domain-dependent (19) , and as expected in the presence of 3 nM TIMP-2, MT1-MMP cells could activate full-length but not MMP-2⌬CD (Fig. 7, lanes 8 and 9) . Vector control cells were unable to activate full-length MMP-2 or MMP-2⌬CD whether TIMP-2 was present (Fig. 7, lanes 10 and 11) or not (Fig. 7,  lanes 2 and 3) . To detect the presence of any MMP-2⌬CD in cell extracts we developed these zymograms for 48 h compared to 24 h in Fig. 5 , but MMP-2⌬CD was never found in the cell extracts. At these longer development times some pro-MMP-2 was now revealed associated with the cell extracts of vector control cells. Hence, these data confirmed that the MMP-2 hemopexin C domain is essential for activation of MMP-2 by MT2-MMP in the TIMP-2-independent pathway and that binding of the pro-MMP-2 to the cell surface via the MMP-2 hemopexin C domain is involved.
DISCUSSION
Utilizing a cell line derived from a Timp2Ϫ/Ϫ knockout mouse that unequivocally lacks TIMP-2 expression, we demonstrated that activation of MMP-2 by cell surface MT2-MMP occurred via a TIMP-2-independent pathway in a hemopexin C domain-dependent manner. The requirement for TIMP-2 in the cellular activation of MMP-2 by MT2-MMP has not been specifically investigated previously. Timp2Ϫ/Ϫ mice and cell lines have only recently been generated (25, 26) , and prior MT2-MMP studies used transfected COS cells that also express TIMP-2 (41) (42) (43) . Indeed, the COS cell studies generated conflicting data on the ability of hMT2-MMP to activate MMP-2. Potentially, this was caused by variation in the levels of endogenous TIMP-2 and recombinant MT2-MMP expression between clones, due to the transient nature of the expression system and may have resulted in the lack of activation reported by Miyamori et al. (43) . In agreement with Hotary et al. (41) , we found that hMT2-MMP activated MMP-2, but we have also demonstrated the novel finding that TIMP-2 was not required for activation.
Biochemical studies have shown that, like MMP-2 activation mediated by soluble MT1-MMP (16, 22) , activation of MMP-2 by the recombinant MT2-MMP catalytic domain can occur in the absence of TIMP-2, if the concentration of MT2-MMP used is at an unphysiologically high level (31, 32) . It is important to emphasize that in the present study the expression levels of MT2-MMP mRNA in the recombinant cell lines were 10-fold lower than that of MT1-MMP in MT1-MMP transfectants. The TIMP-2-independent activation of MMP-2 by MT2-MMP was not therefore the result of a high local concentration of MT2-MMP. Indeed these results indicate that the TIMP-2-independent activation pathway is highly efficient, requiring only very low levels of MT2-MMP expression, and likely involves binding interactions or partners not replicated in studies using the isolated catalytic domain in solution.
Localization and recruitment of proteinases at the cell surface serves to increase the local enzyme concentration for focal proteolysis within the pericellular environment and lead to efficient substrate cleavage. Similar effects enhance MMP-2 MMP-2 activation by MT2-MMP, like MT1-MMP (19) , involved cell surface interaction of MMP-2 and was MMP-2 hemopexin C domain-dependent (Figs. 5, 6 , and 7). Using MMP-2⌬CD (Fig. 7) , we showed that the MMP-2 hemopexin C domain is essential for binding of MMP-2 to the cell surface for initiating activation. The competition experiments (Fig. 6) showed that the hemopexin C domain is also required for the final activation cleavage. Of note, an MT1-MMP-mediated TIMP-2-independent activation pathway that also involves hemopexin C domain interaction has been reported for MMP-13 (11) , but the nature of the cell surface association has yet to be elucidated. There are several potential mechanisms by which MT2-MMP could activate MMP-2 in a TIMP-2-independent manner that involves cell surface interaction of the MMP-2 via the hemopexin C domain. These include MMP-2 binding to: (i) a novel receptor, (ii) integrins such as ␣ v ␤ 3 , (iii) MT2-MMP directly, or (iv) MT2-MMP via a novel bridging protein. A number of alternative pathways for MMP-2 activation by MT1-MMP have been reported involving both novel receptors such as tissue transglutaminase (54) and integrins (55) (56) (57) . However, for MT2-MMP, binding of MMP-2 to these receptors is unlikely, because exogenous MMP-2 was not detected in extracts of cells transfected with the vector alone or cells expressing MT1-MMP in the absence of TIMP-2 ( Fig. 5 ) except after prolonged incubation of the zymogram (Fig. 7) . It seems more likely that MMP-2 binds directly or via a novel extracellular bridging protein to MT2-MMP or to a novel receptor of which MT2-MMP is a component. Very recently, a TIMP-2-independent activation pathway for MMP-2 was demonstrated in endothelial cells involving claudin-5 (44). However, we cannot detect claudin-5 in the Timp2Ϫ/Ϫ fibroblasts by RT-PCR. 3 Other candidates for alternative bridging proteins include TIMP-1 and TIMP-3, both of which are expressed in the Timp2Ϫ/Ϫ cells. TIMP-1 is unlikely to be involved, because it is a relatively poor inhibitor of MT2-MMP and does not bind pro-MMP-2 (58). TIMP-3 binds to the hemopexin C domain of pro-MMP-2 (59) and inhibits MT2-MMP (31) with a similar k on to both TIMP-2 and TIMP-4. However, this does not necessarily indicate that TIMP-3 can support activation of MMP-2 by MT2-MMP. TIMP-4 also binds to pro-MMP-2 hemopexin C domain (28, 29) , MT1-MMP (28), and MT2-MMP (shown here) but is unable to promote pro-MMP-2 activation by either MT1-MMP (28) or MT2-MMP. Without structural data for MT2-MMP, it is hard to predict differences in the structure of MT2-MMP and MT1-MMP that could account for differences in pro-MMP-2 activation. MT2-MMP shows a high degree of similarity (73.9%) with MT1-MMP, but MT2-MMP does have longer linker regions between both the catalytic and hemopexin C domains, and the hemopexin C domain and the transmembrane domain (5) . One significant difference between MT2-MMP and MT1-MMP, which may be of relevance to MMP-2 activation, arises from the presence of an RGD sequence (at amino acid positions 495-497) in the hemopexin C domain of MT2-MMP (5). The RGD sequence may be involved in binding of MT2-MMP to integrins, which together form a receptor for MMP-2. The mechanisms involved in pro-MMP-2 activation by MT2-MMP, including the potential roles of the RGD sequence and TIMP-3, are currently under investigation using recombinant MT2-MMP hemopexin C domains.
Although precedents for alternative MMP-2 activation pathways have been established, the significance of multiple potential activators for MMP-2 in vivo has not been determined. Activation of MMP-2 by MT2-MMP was rapid; the lag period before activation was much shorter than that observed for TIMP-2-dependent activation by MT1-MMP. However, the level of MMP-2 activation by MT2-MMP rarely reached the levels observed for activation by MT1-MMP in the presence of TIMP-2. Indeed, evidence from MT1-MMP null mice would suggest that MT1-MMP is the primary route for MMP-2 activation under normal conditions. Skin and lung tissue from MT1-MMP null mice showed impaired MMP-2 activation (30) , suggesting that at least in these tissues MT2-MMP could not completely substitute for MT1-MMP. Similarly, in TIMP-2 null mice MMP-2 activation was not detected in lung extracts (25) , whereas reduced activation was observed in lung extracts from mice expressing a deletion mutant of TIMP-2 with impaired inhibitory activity (26) . However, the levels of MT2-MMP in the lung have not been reported and may be low. Potentially, activated MMP-2 in Timp2Ϫ/Ϫ mice may be detected in tissues and pathologies where MT2-MMP is highly expressed. Elevated levels of MT2-MMP have been reported in human glioblastomas (39, 40) , breast, and urothelial carcinomas (37, 38) and may provide an alternative mechanism for MMP-2 activation in these tumors.
We suggest that MT2-MMP may serve to activate MMP-2 in processes and tissues characterized by MT2-MMP induction and low levels of TIMP-2. However, in situations where TIMP-2 levels become elevated to concentrations that support the efficient and highly regulated activation of MMP-2 by MT1-MMP, TIMP-2 concomitantly leads to inhibition of activation by MT2-MMP. The fine level of control exerted by the complex regulatory mechanisms governing MMP-2 activation by MT1-MMP would then dominate. This requires further study, but potentially adds another layer of complexity to the control of MMP-2 activation in vivo.
